A novel controlled-release system for antibacterial enzyme lysostaphin delivery using hydroxyapatite/chitosan composite bone cement.

ANOVA was employed to assess significance with P values less than 0.05 (*, significant), 0.01 (**, very significant) and 0.001 (***, extremely significant). 1.8 Ethics statement All experiments carried out in vivo in this study were in compliance with the recommendations in the Animal Management Rules of the Ministry of Health of the People's Republic of China (Document No. 55, 2001) and approved by the Ethics Committee of Fudan University. 1.9 Experiment caveats The following should be advised as the caveats to the experiments in this study: The presence of lysostaphin in the tissue of the in vivo drug release experiments was not tested.

also in 7,787 other papers